FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133323475> ?p ?o ?g. }

• W3133323475 abstract "There are diverse studies which afford evidences that risperidone is as effective as second generation antipsychotics in treating positive symptoms and more effective in treatment of negative symptoms. This study is intended to find the clinical efficacy and safety profile of lurasidone comparing with risperidone, a drug in common use nowadays. Patients aged between 18 to 60yrs, Patients with new onset of symptoms who fulfil the ICD-10 criteria for a primary diagnosis of schizophrenia and Patients having a total PANSS score of ≥80 including a score ≥4 (moderate) on two or more of positive subscale at baseline. Patients with acute exacerbation of schizophrenia who remained drug free for at least last 6 months also included. Demographic data of the patients were collected. Baseline investigations like BP, complete blood count, lipid profile, blood sugar, renal function test and liver function test were done. Severity of schizophrenia at baseline was assessed using positive and negative symptoms scale (PANSS). Patients were randomized by using computer generated random table in 1:1 ratio as group A and group B, with 25 patients in each group. The efficacy of group A and group B was analysed by applying rating scale Positive and negative syndrome scale (PANSS) at the end of 4 and 6 weeks. Adverse drug reactions were recorded and monitored by interviewing with patients, by physical examination and also by necessary lab investigations at the end of 6 weeks. Patients were insisted to maintain a diary to note any new occurrence of adverse drug reactions in between the follow up period. Suspected adverse drug reactions were documented in predesigned reporting form. In PANSS positive scale both groups had significant decrease in PANSS score both at week 4 and week 6 (p<0.05). Lurasidone is as equally efficacious as risperidone in reducing PANSS score, but produces less metabolic syndrome and other adverse effects than risperidone." @default.
• W3133323475 created "2021-03-01" @default.
• W3133323475 creator A5008411230 @default.
• W3133323475 creator A5008788123 @default.
• W3133323475 creator A5016989977 @default.
• W3133323475 creator A5023961865 @default.
• W3133323475 creator A5037060136 @default.
• W3133323475 creator A5038941324 @default.
• W3133323475 creator A5048931787 @default.
• W3133323475 creator A5051748161 @default.
• W3133323475 creator A5055315436 @default.
• W3133323475 creator A5055941717 @default.
• W3133323475 creator A5064101987 @default.
• W3133323475 creator A5078897053 @default.
• W3133323475 date "2021-02-23" @default.
• W3133323475 modified "2023-10-17" @default.
• W3133323475 title "Clinical Efficacy and Safety Profile of Lurasidone Comparing with Risperidone: Randomized, Open Label, Clinical Study" @default.
• W3133323475 doi "https://doi.org/10.9734/jpri/2021/v33i431167" @default.
• W3133323475 hasPublicationYear "2021" @default.
• W3133323475 type Work @default.
• W3133323475 sameAs 3133323475 @default.
• W3133323475 citedByCount "0" @default.
• W3133323475 crossrefType "journal-article" @default.
• W3133323475 hasAuthorship W3133323475A5008411230 @default.
• W3133323475 hasAuthorship W3133323475A5008788123 @default.
• W3133323475 hasAuthorship W3133323475A5016989977 @default.
• W3133323475 hasAuthorship W3133323475A5023961865 @default.
• W3133323475 hasAuthorship W3133323475A5037060136 @default.
• W3133323475 hasAuthorship W3133323475A5038941324 @default.
• W3133323475 hasAuthorship W3133323475A5048931787 @default.
• W3133323475 hasAuthorship W3133323475A5051748161 @default.
• W3133323475 hasAuthorship W3133323475A5055315436 @default.
• W3133323475 hasAuthorship W3133323475A5055941717 @default.
• W3133323475 hasAuthorship W3133323475A5064101987 @default.
• W3133323475 hasAuthorship W3133323475A5078897053 @default.
• W3133323475 hasBestOaLocation W31333234751 @default.
• W3133323475 hasConcept C118552586 @default.
• W3133323475 hasConcept C126322002 @default.
• W3133323475 hasConcept C168563851 @default.
• W3133323475 hasConcept C197934379 @default.
• W3133323475 hasConcept C2776412080 @default.
• W3133323475 hasConcept C2776701107 @default.
• W3133323475 hasConcept C2777014857 @default.
• W3133323475 hasConcept C2779727114 @default.
• W3133323475 hasConcept C2780057945 @default.
• W3133323475 hasConcept C2780135775 @default.
• W3133323475 hasConcept C2780494398 @default.
• W3133323475 hasConcept C71924100 @default.
• W3133323475 hasConceptScore W3133323475C118552586 @default.
• W3133323475 hasConceptScore W3133323475C126322002 @default.
• W3133323475 hasConceptScore W3133323475C168563851 @default.
• W3133323475 hasConceptScore W3133323475C197934379 @default.
• W3133323475 hasConceptScore W3133323475C2776412080 @default.
• W3133323475 hasConceptScore W3133323475C2776701107 @default.
• W3133323475 hasConceptScore W3133323475C2777014857 @default.
• W3133323475 hasConceptScore W3133323475C2779727114 @default.
• W3133323475 hasConceptScore W3133323475C2780057945 @default.
• W3133323475 hasConceptScore W3133323475C2780135775 @default.
• W3133323475 hasConceptScore W3133323475C2780494398 @default.
• W3133323475 hasConceptScore W3133323475C71924100 @default.
• W3133323475 hasLocation W31333234751 @default.
• W3133323475 hasOpenAccess W3133323475 @default.
• W3133323475 hasPrimaryLocation W31333234751 @default.
• W3133323475 hasRelatedWork W11970049 @default.
• W3133323475 hasRelatedWork W12959130 @default.
• W3133323475 hasRelatedWork W13454653 @default.
• W3133323475 hasRelatedWork W14118903 @default.
• W3133323475 hasRelatedWork W14942699 @default.
• W3133323475 hasRelatedWork W1742370 @default.
• W3133323475 hasRelatedWork W2507035 @default.
• W3133323475 hasRelatedWork W5032858 @default.
• W3133323475 hasRelatedWork W7444904 @default.
• W3133323475 hasRelatedWork W9412413 @default.
• W3133323475 isParatext "false" @default.
• W3133323475 isRetracted "false" @default.
• W3133323475 magId "3133323475" @default.
• W3133323475 workType "article" @default.